Marcel Verheij, MD, PhD, of Radboud University Medical Center, presents findings from the phase II CRITICS-II trial, which compared three preoperative regimens while omitting adjuvant treatment among patients with nonmetastatic resectable gastric cancer: chemotherapy, chemotherapy followed by chemoradiotherapy, and chemoradiotherapy (Abstract 283).
Daniela Molena, MD, of Memorial Sloan Kettering Cancer Center, discusses a comparison of the surgical journeys of patients with resectable gastric/gastroesophageal adenocarcinoma who either received fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab or FLOT plus placebo in the MATTERHORN study (Abstract 353).
Samuel J. Klempner, MD, of Massachusetts General Hospital, discusses results from the phase II ILUSTRO trial, which evaluated the combination of the anti-CLDN18.2 antibody zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive; HER2-negative; locally advanced, unresectable, or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma (Abstract LBA284).
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, outlines an assessment of baseline characteristics and safety outcomes in HIMALAYA trial participants who were rechallenged with tremelimumab after being treated with the STRIDE regimen (single dose of tremelimumab plus regular-interval durvalumab) (Abstract 541).
Elizabeth Smyth, MD, of the Oxford NIHR Biomedical Research Centre, Churchill Hospital, presents findings from an analysis of the MATTERHORN trial, a phase III study that examined fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab in patients with resectable gastric/gastroesophageal junction cancer. Dr. Smyth discusses rates of FLOT discontinuation along with event-free survival based on FLOT completion status in the trial (Abstract 343).
Dina Ioffe, MD, of Fox Chase Cancer Center, describes the results of an analysis that sought to determine how race/ethnicity, insurance status, and socioeconomic status may affect patterns of systemic treatment for metastatic hepatocellular carcinoma (HCC) (Abstract 489).
